Advancing the Future of

CANCER CARE

With scientific curiosity and dedication to patients, we strive every day to improve the futures of people living with cancer

Our Research and Development

Our Science

Sort

EGFR Targeting

mAbs

Learn about Merck’s research into the monoclonal antibody, cetuximab, that induces tumor cell death by blocking the epidermal growth factor receptor (EGFR) and disrupting
EGFR signaling

10 Min

Our HCP Resources

GL-MULO-00232 | December 2025